For years, We have focused on exploiting elevations of the NQO1 levels in numerous solid tumors, particularly in non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and breast cancer25, 26, for drug development. Here, NQO1 is linked to non-small cell lung carcinoma.